Article
PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients.
Scientific reports - 13 Jun 2022
Hsu Kuo-Hsuan, Tseng Jeng-Sen, Yang Tsung-Ying, Chen Kun-Chieh, Su Kang-Yi, Yu Sung-Liang, Chen Jeremy J W, Huang Yen-Hsiang, Chang Gee-Chen
Abstract excerpt
The impact of strong Programmed Death-ligand 1 (PD-L1) expression on the clinical outcomes of osimertinib in treatment naïve advanced Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC) patients remains uncertain. We enrolled advanced NSCLC patients who harbored sensitizing EGFR mutation and were treated first-line with osimertinib between 2017 and 2021. The PD-L1 expression level...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.